Literature DB >> 24009289

Tubulointerstitial nephritis and cancer chemotherapy: update on a neglected clinical entity.

Medha Airy1, Rajeev Raghavan, Luan D Truong, Garabed Eknoyan.   

Abstract

BACKGROUND: Cancer patients are particularly vulnerable to drug-induced kidney injury during their chemotherapy. Whereas the direct nephrotoxic effects of these drugs are well recognized, that of tubulointerstitial nephritis (TIN) is less well known, underdiagnosed and often reported only as a functional tubular disorder. The diagnosis of acute TIN is important because of its insidious onset with tubular dysfunction, its potential reversibility if detected early and the possibility of its response to steroid treatment.
METHODS: We performed a literature review (44 cases) and reviewed our institutional biopsy register (12 cases) of patients on cancer chemotherapy with documented TIN. Biopsies were considered in three groups: acute TIN, chronic TIN and acute on chronic TIN. The outcomes that were evaluated were recovery of kidney function, development of chronic kidney disease and onset of end-stage renal disease (ESRD).
RESULTS: Ifosfamide, BCG, tyrosine kinase inhibitors and premetrexed were the most commonly implicated drugs. Ifosfamide and premetrexed were associated with worst outcomes. Recovery of kidney function was better in acute TIN (ATIN) (29%) with fewer progressing to ESRD (12.9%) than with chronic TIN (7.6% recovery, 15.3% ESRD). Steroid use appeared to favorably alter outcomes in ATIN (40% recovery) compared with conservative treatment (18.75% recovery). Peak serum creatinine, age, gender and type of malignancy did not influence outcomes.
CONCLUSIONS: As a potentially reversible lesion that can respond to withdrawal of the suspected agent, and in some cases to a short course of steroid therapy, it is important to consider ATIN in the differential diagnosis of all cases of acute kidney injury in cancer patients on chemotherapy.

Entities:  

Keywords:  acute kidney injury; cancer chemotherapy toxicity; nephrotoxicity; tubulointerstitial nephritis

Mesh:

Year:  2013        PMID: 24009289     DOI: 10.1093/ndt/gft241

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

1.  Onconephrology: An Evolving Field.

Authors:  Ala Abudayyeh
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

2.  Successful delivery of chemotherapy to treat small-cell prostate cancer in a patient undergoing haemodialysis.

Authors:  Andrew McPartlin; Claudia Grimaldo; Jeanette Lyons; Daniel Burke; Sandip Mitra; Ananya Choudhury
Journal:  Clin Kidney J       Date:  2014-09-16

Review 3.  Anticancer Drug-Induced Acute Kidney Injury.

Authors:  Hassan Izzedine; Mark A Perazella
Journal:  Kidney Int Rep       Date:  2017-02-16

4.  Renal failure during chemotherapy: renal biopsy for assessing subacute nephrotoxicity of pemetrexed.

Authors:  Maureen Assayag; Philippe Rouvier; Marion Gauthier; Ghania Costel; Philippe Cluzel; Lucile Mercadal; Gilbert Deray; Corinne Isnard Bagnis
Journal:  BMC Cancer       Date:  2017-11-16       Impact factor: 4.430

Review 5.  The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma.

Authors:  Tucci Marco; Passarelli Anna; Todisco Annalisa; Mannavola Francesco; Stucci Luigia Stefania; D'Oronzo Stella; Rossini Michele; Taurisano Marco; Gesualdo Loreto; Silvestris Franco
Journal:  Ther Adv Med Oncol       Date:  2019-09-24       Impact factor: 8.168

6.  Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.

Authors:  Melissa Pilco Teran; Ana Merino Ribas; Nadia Martin Alemany; Xoana Barros Freiria; Jordi Rubio Casadevall; Ferran Pérez Bueno; Isabel García Méndez; Marcela Castillo Devia; Cristina Noboa Paez; Pere Torguet Escuder; Jordi Calabia Martínez
Journal:  Invest New Drugs       Date:  2020-07-09       Impact factor: 3.850

7.  [Subacute kidney injury in a 40-year-old female Northern African patient].

Authors:  T Chahoud-Schriefer; T Wiech; G Schäfer; S Harendza
Journal:  Internist (Berl)       Date:  2021-02-22       Impact factor: 0.743

8.  Karyomegalic interstitial nephropathy following ifosfamide therapy.

Authors:  R Jayasurya; B H Srinivas; M Ponraj; S Haridasan; S Parameswaran; P S Priyamvada
Journal:  Indian J Nephrol       Date:  2016 Jul-Aug

Review 9.  Acute interstitial nephritis - a reappraisal and update.

Authors:  Rajeev Raghavan; Garabed Eknoyan
Journal:  Clin Nephrol       Date:  2014-09       Impact factor: 0.975

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.